IMNM biotech catalysts & pipeline

IMMUNOME INC · Data as of 2026-10-25

Upcoming catalysts

IM-1021 — Initial data

2026

Immunome expects to present initial lymphoma data for IM-1021 in 2026.

Source filing

solid tumor-targeted ADC programs — IND submission

2026

Three IND submissions for solid tumor-targeted ADC programs planned in 2026

Source filing

IM-1335 — IND submission

late 2026

Immunome expects to submit Investigational New Drug applications (INDs) for IM-1340 and IM-1335 in mid- and late 2026, respectively.

Source filing

varegacestat (formerly AL102) — NDA/BLA submission

Late 2026

Immunome plans to submit a Marketing Authorization Application to the European Medicines Agency for varegacestat by the end of 2026.

Source filing

varegacestat (formerly AL102) — PDUFA

Apr 28

Varegacestat PDUFA target action date set for April 28, 2027, following U.S. FDA acceptance of New Drug Application (NDA) for adults with desmoid tumors

Source filing

Explore the free biotech catalyst calendar